Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Many commercially available glucagon products for treatment of severe hypoglycaemia require cumbersome reconstitution and potentially intimidating injection during an emergency. Nasal glucagon (NG) is a novel drug-device combination product consisting of a single-use dosing device that delivers glucagon dry powder through nasal administration. The present study assessed whether 3 mg NG was non-inferior to 1 mg intramuscular glucagon (IMG) in adults with type 1 diabetes. METHODS: This randomised, open-label, two-period, crossover trial was conducted at two clinical sites. Hypoglycaemia (plasma glucose [PG] target of < 3.3 mmol/l (60 mg/dl) was induced by an intravenous insulin infusion. Glucagon preparations were given by study staff. Treatment success was defined as an increase in PG to ≥ 3.9 mmol/l (70 mg/dl) or an increase of ≥ 1.1 mmol/l (20 mg/dl) from the PG nadir within 30 min of receiving glucagon. RESULTS: Of the 66 participants included in the primary efficacy analysis who received both NG and IMG, 100% achieved treatment success, thus demonstrating non-inferiority of NG to IMG. All participants achieved treatment success within 25 min with the mean time to treatment success of 11.4 min (NG) and 9.9 min (IMG). No serious adverse events occurred. Forty-eight treatment-emergent adverse events (TEAEs) occurred after NG and 51 after IMG. Most TEAEs were mild and transient. CONCLUSION: Nasal glucagon was as efficacious and well tolerated as IMG for the treatment of insulin-induced hypoglycaemia in adults and will be as useful as IMG as a rescue treatment for severe hypoglycaemia. TRIAL REGISTRATION: NCT03339453, ClinicalTrials.gov.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Kaplan-Meier curve for the time to treatment success (an increase in PG to ≥ 3.9 mmol/l [70 mg/dl] or a PG increase of ≥ 1.1 mmol/l [20 mg/dl] from nadir) within 30 min following 3 mg nasal glucagon and 1 mg GlucaGen® treatment in participants who completed all dosing visits. Red line = 3 mg nasal glucagon (N = 68); black line = 1 mg intramuscular glucagon (N = 69). IM intra-muscular, PG plasma glucose](https://figures.cochat.ai/paper-figures/04197c94473045d0839ec752fab3d91e/glucagon-administration-by-nasal-and-intramuscular-routes-in-adults-with-type-1-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, intranasal and ready-to-inject glucagon preparations are now widely available and are preferred due to their ease of administration resulting in more rapid correction of hypoglycemia (143-145).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [144]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608
The International Hypoglycaemia Study Group (2017) · Diabetologia · doi:10.1007/s00125-016-4146-6 · Cited by 360
Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis
Simons, F. E. R., Prenner, B. M., & Finn, A. F. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.168 · Cited by 135
Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
Kedia (2011) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s20633 · Cited by 131
Rickels, M. R., Ruedy, K. J., Foster, N. C., Piché, C. A., Dulude, H., Sherr, J. L., Tamborlane, W. V., Bethin, K. E., DiMeglio, L. A., Wadwa, R. P., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1498 · Cited by 128
Self-citationYale, J.-F., Dulude, H., Egeth, M., Piché, C. A., Lafontaine, M., Carballo, D., Margolies, R., Dissinger, E., Shames, A. R., Kaplowitz, N., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0460 · Cited by 88
Self-citationYanez, N. D., Kronmal, R. A., & Shemanski, L. R. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981130)17:22<2597::aid-sim940>3.0.co;2-g · Cited by 77
Glucagon administration – underevaluated and undertaught
Harrism, G., Diment, A., Sulway, M., & Wilkinson, M. (2001) · Practical Diabetes International · doi:10.1002/pdi.138 · Cited by 71
Seaquist, E. R., Dulude, H., Zhang, X. M., Rabasa‐Lhoret, R., Tsoukas, G. M., Conway, J. R., Weisnagel, S. J., Gerety, G., Woo, V. C., Zhang, S., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13278 · Cited by 54
Self-citationCeriello, A., Novials, A., Ortega, E., Pujadas, G., Sala, L. L., Testa, R., Bonfigli, A. R., & Genovese, S. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.05.003 · Cited by 52
Research works printed but not linked: 1
- Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med. 1998;17(22):2635–50. · DOI · Paper page
Cited by
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s006 · Cited by 486
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s006 · Cited by 440
Jeong, S.-H., Jang, J.-H., & Lee, Y.-B. (2023) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00589-5 · Cited by 256
6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s006 · Cited by 172
The past, present, and future physiology and pharmacology of glucagon
Capozzi, M. E., D’Alessio, D. A., & Campbell, J. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.001 · Cited by 109
Metadata
- Authors
- Suico, J. G., Hövelmann, U., Zhang, S., Shen, T., Bergman, B., Sherr, J., Zijlstra, E., Frier, B. M., & Plum-Mörschel, L.
- Affiliations
- Eli Lilly (United States) (US)
- Profil Institute for Metabolic Research (DE)
- Yale University (US)
- The Queen's Medical Research Institute (GB)
- Corresponding author
- Suico, Jeffrey G.
- ORCID
- Venue
- Diabetes Therapy
- Published
- 2020-06-08
- Volume
- 11
- Issue
- 7
- Pages
- 1591-1603
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC7324463
- OpenAlex
- W3033451567
- Semantic Scholar
- e87b010b1bdb96eb28eeb7d0d02ddf0cc63ebce0
- Cited by
- 32
- References
- 13
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 5 · 2023: 10 · 2022: 6 · 2021: 4
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- nasal glucagon, type 1 diabetes, severe hypoglycemia, insulin-induced hypoglycemia, drug-device combination products, non-inferiority, treatment success, adverse events
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study. https://app.cochat.ai/papers/10.1007/s13300-020-00845-7
- The paper
- Suico, J. G., Hövelmann, U., Zhang, S., Shen, T., Bergman, B., Sherr, J., Zijlstra, E., Frier, B. M., & Plum-Mörschel, L. (2020). Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study. Diabetes Therapy. https://doi.org/10.1007/s13300-020-00845-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.